York、PAにおける非小細胞肺癌の臨床試験
Yorkとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する15件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Cancer Care Associates Of York /ID# 270971, York
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- WellSpan Health-York Cancer Center, York
- WellSpan Health-York Hospital, York
- UPMC Memorial, York
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- WellSpan York Cancer Center, York
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
被験者募集中第3相
- WellSpan Oncology Research, York
Pan-tumor MRD Study
被験者募集中観察研究
- Cancer Care Associates of York (CCAY), York
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
被験者募集中第3相
- WellSpan Oncology Research, York
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Research Site, York
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
被験者募集中観察研究
- WellSpan Medical Oncology & Hematology at York Cancer Center, York
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
被験者募集中第2相
- WellSpan Health-York Cancer Center, York
- UPMC Memorial, York
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- Cancer Care Associates of York, York
- WellSpan Health-York Cancer Center, York
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2/3相
- Cancer Care Associates of York, York
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- Cancer Care Associates of York, York
- WellSpan Health-York Cancer Center, York
- WellSpan Health-York Hospital, York
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- WellSpan Health - York Cancer Center, York
GEMINI-NSCLC: NSCLC Biomarker Study
被験者募集中観察研究
- Cancer Care Associates of York, York
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
被験者募集中第1/2相
- Cancer Care Associates of York (site 206), York
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Yorkにおける他の研究
- がん（全種類）8件の研究
- 乳がん8件の研究
- 肺がん8件の研究
- 頭頸部扁平上皮癌7件の研究
- 卵巣がん6件の研究
- 前立腺がん5件の研究
- 冠動脈疾患5件の研究
- 食道癌4件の研究
- トリプルネガティブ乳がん4件の研究
- 大腸癌4件の研究
- 子宮内膜がん4件の研究
- 結腸癌3件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。